J Cancer 2022; 13(11):3209-3220. doi:10.7150/jca.76695 This issue Cite

Review

KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer

Manxiong Dai1,3, Shaofeng Chen1,3, Xiong Teng1,3, Kang Chen1,3✉, Wei Cheng1,2 3✉

1. Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, 410005 Hunan Province, China.
2. Xiangyue Hospital Affiliated to Hunan Institute of Parasitic Diseases, National Clinical Center for Schistosomiasis Treatment, Yueyang 414000, Hunan Province, China.
3. Translational Medicine Laboratory of Pancreas Disease of Hunan Normal University, Changsha 410005, China.

Citation:
Dai M, Chen S, Teng X, Chen K, Cheng W. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. J Cancer 2022; 13(11):3209-3220. doi:10.7150/jca.76695. https://www.jcancer.org/v13p3209.htm
Other styles

File import instruction

Abstract

Graphic abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors, with a 5-year survival rate of less than 10%. At present, the comprehensive treatment based on surgery, radiotherapy and chemotherapy has encountered a bottleneck, and targeted immunotherapy turns to be the direction of future development. About 90% of PDAC patients have KRAS mutations, and KRAS has been widely used in the diagnosis, treatment, and prognosis of PDAC in recent years. With the development of liquid biopsy and gene testing, KRAS is expected to become a new biomarker to assist the stratification and prognosis of PDAC patients. An increasing number of small molecule inhibitors acting on the KRAS pathway are being developed and put into the clinic, providing more options for PDAC patients.

Keywords: Pancreatic neoplasms, KRAS gene, Targeted therapy, Diagnosis, Review


Citation styles

APA
Dai, M., Chen, S., Teng, X., Chen, K., Cheng, W. (2022). KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. Journal of Cancer, 13(11), 3209-3220. https://doi.org/10.7150/jca.76695.

ACS
Dai, M.; Chen, S.; Teng, X.; Chen, K.; Cheng, W. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. J. Cancer 2022, 13 (11), 3209-3220. DOI: 10.7150/jca.76695.

NLM
Dai M, Chen S, Teng X, Chen K, Cheng W. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. J Cancer 2022; 13(11):3209-3220. doi:10.7150/jca.76695. https://www.jcancer.org/v13p3209.htm

CSE
Dai M, Chen S, Teng X, Chen K, Cheng W. 2022. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. J Cancer. 13(11):3209-3220.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.